Patent intelligence · US
US 10213388
Abuse resistant oral dosage forms
Abuse resistant oral dosage forms
Patent details — US 10213388
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 26, 2019
- Expiration
- Feb 21, 2039
- Applicant
- Elite Laboratories, Inc.
- Claims
- 9
- CPC classes
- A61K, A61K31/485, A61K9/2027, A61K9/2095
Quick answer
US 10213388 (Abuse resistant oral dosage forms) is held by Elite Laboratories, Inc.. Status: granted. Granted Feb 26, 2019. Expires Feb 21, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Elite Laboratories, Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/485, A61K9/2027, A61K9/2095, A61K9/28, A61K9/2846
More from Elite Laboratories, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364693
Methods of treating metabolic diseases with fused bicyclic pyrazoles
granted -
US 12295394
Water-soluble additive composition
granted -
US 12116596
Method and apparatus for improved mesenchymal stem cell harvesting
granted -
US 12016853
Methods of treating RBP4 related diseases with triazolopyridines
granted -
US 11951100
Formulations of RBP4 inhibitors and methods of use
granted -
US 11723873
Oral dosage form of ticagrelor and preparation method thereof
granted -
US 11684596
Antidiabetic pharmaceutical compositions and preparation method thereof
granted -
US 11655454
Method and apparatus for improved mesenchymal stem cell harvesting
granted
Frequently asked questions
What is US patent 10213388?
US 10213388 (Abuse resistant oral dosage forms) is held by Elite Laboratories, Inc.. Status: granted. Granted Feb 26, 2019. Expires Feb 21, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10213388?
Elite Laboratories, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 10213388 expire?
Our index shows an expiration date of Feb 21, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.